To evaluate ziprasidone for the treatment of schizophrenia with respect to its
pharmacology, pharmacokinetics, adverse effect profiles, and drug interaction
potential.
Data Source:
A MEDLINE search (1966-May 2001) was conducted for primary and secondary sources
focusing on atypical antipsychotics and ziprasidone.
Study Selection:
All of the articles identified from the data source were evaluated and all
information deemed relevant was included.
Data Synthesis:
Like other atypical antipsychotics, ziprasidone works by blocking serotonin and
dopamine receptors in the mesolimbic and mesocortical regions of the brain.
Ziprasidone is equally effective as haloperidol in treating schizophrenia or
schizoaffective disorders. A proposed advantage of ziprasidone over other atypical
antipsychotics is lower incidence of weight gain. As with a number of other
psychotropic agents such as thioridazine, prolongation of the QTc interval should
be monitored for patients receiving ziprasidone.
Conclusions:
Based on adverse effect profiles and relatively fewer drug interactions,
ziprasidone is recommended for patients who are elderly and taking multiple
medications.
MallA. Understanding symptoms of
schizophrenia. Can J Psychiatry1995; 40 (suppl 1):
S12–7.
3.
WorrelJMarkenPBeckmanSRuehterV. Atypical antipsychotic agents: A critical
review. Am J Health Syst Pharm2000; 57:
238–55.
4.
JenssenL. New treatment options for
schizophrenia. U S Pharm1998; 23:
117–26.
5.
LiebermanJ. Understanding the mechanism of action of atypical
antipsychotic drugs. Br J Psychiatry1993; 163 (suppl 22):
7–18.
6.
KapurSRemingtonG. Serotonin-dopamine interaction and its relevance to
schizophrenia. Am J Psychiatry1996; 153:
466–76.
7.
HonigfieldGArellanoFSethiJBianchiniAScheinJ. Reducing clozapine-related morbidity and mortality; 5
years of experience with the Clozaril national registry. J
Clin Psychiatry1998; 59 (suppl 3):
3–7.
8.
ReevesKHarriganE. The efficacy and safety of two final doses of
ziprasidone in schizophrenia and schizoaffective disorder.
Eur Psychiatry1996; 11 (suppl 4):
422S.
9.
SeegerTSeymourPSchmidtAZornSSchultzDLebelA, Ziprasidone (CP-88,059): A new antipsychotic with
combined dopamine and serotonin receptor antagonist activity.
J Pharmacol Exp Ther1995; 275:
101–13.
10.
KapurS. A new framework for investigating antipsychotic
action in humans: Lessons from PET imaging. Mol
Psychiatry1998; 3:
135–40.
11.
StipE. Novel antipsychotics: Issues and controversies.
Typicality of atypical antipsychotics. J Psychiatry
Neurosci2000; 25:
137–53.
12.
BenchCLammertsmaAGrasbyPDolanRWarringtonSBoyceM, The time course of binding to striatal dopamine
D2 receptors by the neuroleptic ziprasidone (CP-88, 059-01)
determined by positron emission tomography.
Psychopharmacology (Berl)1996; 124:
141–7.
13.
FischmanABonabABabichJAlpertNRauchSElmalehD, Positron emission tomographic analysis of central
5-hydroxytryptamin 2 receptor occupancy in healthy volunteers treated with the
novel antipsychotic agent, ziprasidone. J Pharmacol Exp
Ther1996; 279:
939–47.
14.
BenchCLammertsmaADolanRGrasbyPWarringtonSGunnK, Dose dependent occupancy of central dopamine
D2 receptors by the novel neuroleptic CP-88, 059-1: A study using
positron emission tomography and 11C-raclopride.
Psychopharmacology (Berl)1993; 112:
308–14.
15.
HamelinnBAllardSLaplanteLMiceliJWilnerKTremblayJ, The effect of timing of a standard meal on the
pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent
ziprasidone. Pharmacotherapy1998; 18:
9–15.
16.
EreshefskyL. Pharmacokinetics and drug interactions: Update for
new antipsychotics. J Clin Psychiatry1996; 57 (suppl 11):
12–25.
17.
MarkowitzJBrownCMooreT. Atypical antipsychotics part I: Pharmacology,
pharmacokinetics, and efficacy. Ann Pharmacother1999; 33:
73–85.
18.
PrakashCKamelAGummerusJWilnerK. Metabolism and excretion of a new antipsychotic drug,
ziprasidone, in humans. Drug Metab Dispos1997; 25:
863–72.
19.
GoffDPoseverTHerzLSimmonsJKlettiNLapierreK, An exploratory haloperidol-controlled dose-finding
study of ziprasidone in hospitalized patients with schizophrenia or
schizoaffective disorder. J Clin Psychopharmacol1998; 18:
296–304.
20.
KeckPBuffensteinAFergusonJFeighnerJJaffeWHarriganE, Ziprasidone 40 and 120 mg/day in the acute
exacerbation of schizophrenia and schizoaffective disorder: A 4-week
placebo-controlled trial. Psychopharmacology1998; 140:
173–84.
21.
DanielDZimbroffDPotkinSReevesKHarriganELakshminarayananM, Ziprasidone 80 mg/day and 160 mg/day in the acute
exacerbation of schizophrenia and schizoaffective disorder: A 6-week
placebo-controlled trial. Ziprasidone Study Group.
Neuropsychopharmacology1999; 20:
491–505.
22.
JibsonMTandonR. New atypical antipsychotic
medications. J Psychiatr Res1998; 32:
215–28.
23.
BlinO. A comparative review of new
antipsychotics. Can J Psychiatry1999; 44:
235–44.
24.
TranPDellvaMTollefsonGBeasleyCPotvinJKieslerG. Extrapyramidal symptoms and tolerability of
olanzapine versus haloperidol in the acute treatment of
schizophrenia. J Clin Psychiatry1997; 58:
205–11.
Data on file. Pfizer Inc., summary overall benefit risk
relationship. New York:
Pfizer, 2001.
27.
BrownCMarkowitzJMooreTParkerN. Atypical antipsychotics part II: Adverse effects,
drug interactions, and costs. Ann Pharmacother1999; 33:
210–7.
28.
KerenATzivoniDGavishDLeviJGottliebSBenhorinJ, Etiology, warning signs and therapy of tosade de
pointes: A study of 10 patients. Circulation1981; 64:
1167–74.
29.
CaseyD. Side effect profiles of new antipsychotic
agents. J Clin Psychiatry1996; 57 (suppl 11):
40S–5S.
30.
ByerlyMWebberMBrooksDSnowLWorleyMLescouflairE. Antipsychotic medications and the elderly: Effects on
cognition and implications for use. Drugs Aging2001; 18:
45–61.
31.
KaragianisJ. Olanzapine and weight gain (letter).
Can J Psychiatry2000; 45: 493.
32.
BustilloJBuchananRIrishDBreierA. Differential effect of clozapine on weight: A
controlled study. Am J Psychiatry1996; 153:
817–9.
33.
GuptaSDroneyTAl-SamarraiSKellerPFrankB. Olanzapine: Weight gain and therapeutic
efficacy. J Clin Psychopharmacol1999; 19:
273–5.
34.
LambertiJBellnierTSchwarzkopfS. Weight gain among schizophrenic patients treated with
clozapine. Am J Psychiatry1992; 149:
689–90.
35.
BaptistaT. Body weight gain induced by antipsychotic drugs:
Mechanisms and management. Acta Psychiatr Scand1999; 100:
3–16.
WetterlingT. Bodyweight gain with atypical antipsychotics: A
comparative review. Drug Saf2001; 24:
59–73.
38.
AllisonDMentoreJHeoMChandlerLCappelleriJInfanteM, Antipsychotic-induced weight gain: A comprehensive
research synthesis. Am J Psychiatry1999; 156:
1686–96.
39.
WilliamsonJWyandtC. Treating schizophrenia: New
strategies. Drug Topics2000; 144 (November):
64–71.
40.
MiceliJSmithMRobargeLMorseTLaurentA. The effects of ketoconazole on ziprasidone
pharmacokinetics — A placebo-controlled crossover study in healthy
volunteers. Br J Clin Pharmacol2000; 49 (suppl 1):
71S–6S.
41.
MiceliJAnzianoRRobargeLHansenRLaurentA. The effect of carbamazepine on the steady-state
pharmacokinetics of ziprasidone in healthy volunteers. Br
J Clin Pharmacol2000; 49 (suppl 1):
65S–70S.
42.
ApseloffGMulletDWilnerKAnzianoRTensfeldtTPelletierS, The effects of ziprasidone on steady-state lithium
levels and renal clearance of lithium. Br J Clin
Pharmacol2000; 49 (suppl 1):
61S–4S.
43.
MuirheadGHarnessJHoltPOliverSAnzianoR. Ziprasidone and the pharmacokinetics of a combined
oral contraceptive. Br J Clin Pharmacol2000; 49 (suppl 1):
49S–56S.
